IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene CA9 Ensembl ENSG00000107159 Chromosome 9 Start 35663853 End 35671147
Description Carbonic anhydrase 9 Precursor (EC 4.2.1.1)(Carbonic anhydrase IX)(CA-IX)(CAIX)(Carbonate dehydratase IX)(Membrane antigen MN)(P54/58N)(Renal cell carcinoma-associated antigen G250)(RCC-associated antigen G250)(pMW1) [Source:UniProtKB/Swiss-Prot;Acc:Q16790]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 1383
     Entrez Gene : 768
     UCSC : uc003zxo.3
     GeneCards : 1383
     RefSeq : NM_001216
     CCDS : CCDS6585.1
     Uniprot : Q16790
     Interpro : Q16790
     OMIM : 603179
     GeneTests : CA9
     CGAP : CA9
     PMID : 8661007

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
up 142/175(82%) IHCKaplan-Meier survival curves(P=0.035) 12560438 J Clin Oncol. 2003 Feb 1;21(3):473-82.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  40309_at  0.70  6.27e-3  1.56e-2  2.25  1.62e-10  2.10e-9
 HG_U133A  205199_at  0.27  4.80e-2  6.69e-2  -0.57  3.80e-13  5.00e-13
 HG_U133_Plus2  205199_at  1.26  1.88e-10  1.44e-9  2.39  2.93e-23  5.95e-22
 Stanford  15746  0.87  3.05e-3  3.00e-2  0.18  6.23e-1  8.01e-1
 Agilent_HS_21.6K  6715  0.19  2.62e-2  9.22e-2  0.27  6.76e-3  2.61e-2

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  205199_at  0.38  3.04e-1  8.77e-1  0.48  1.45e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 40309_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 205199_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 205199_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 15746    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 6715    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
carbonic anhydrase ix tumour Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. 14712082 Human
carbonic anhydrase ix invasive breast cancer PURPOSE: To assess the frequency of expression and the prognostic significance of a hypoxia-regulated marker, carbonic anhydrase IX (CA IX), in a cohort of patients with invasive breast cancer. 11504747 Human
ca9 human renal-cell carcinoma Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. 11506497 Human
ca9 tumors CA9 expression in tumors with low vascularization defined a prognosis similar to the one of patients with highly angiogenic tumors. 11691824 Human
ca9 head-and-neck cancers EXPERIMENTAL DESIGN: We assessed the expression of CA9 and the microvessel density (MVD; CD31-positive) in 75 locally advanced squamous cell head and neck cancers treated with concurrent chemoradiotherapy with carboplatin. 11705854 Human
ca9 renal-cell carcinoma These data suggest that hypomethylation in the 5' region may have a major role in expression of the MN/CA9 gene in renal cell carcinoma cells. 10708480 Human
ca9 renal cancer Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients. 10962301 Human
ca 9 tumor MATERIAL AND METHODS: This review focuses on clinical and experimental data, regarding prognostic impact and comparability with other methods of hypoxia detection, for three proteins suggested as endogenous markers of tumor hypoxia: hypoxia-inducible fact 14652668 Human
ca9 tumours Tumours of low clinical stage showed a striking increase in MN/CA9 expression, and high MN/CA9 expression was associated with a good patient outcome. 10368188 Human
carbonic anhydrase ix invasive breast carcinoma The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. 14572156 Human
carbonic anhydrase ix invasive breast carcinoma The value of the fibrotic focus (FF) as a marker of intra-tumoral hypoxia in invasive breast carcinoma was assessed by studying its relationship with the expression of the hypoxia-induced carbonic anhydrase IX (CA IX), angiogenesis indices and prognosis. 14572156 Human
carbonic anhydrase ix kidney cancer Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. 12738749 Mouse
carbonic anhydrase ix tumours Transmembrane carbonic anhydrase IX (CA IX) is frequently expressed in human tumours in response to hypoxia and may serve as a tumour marker and therapeutic target. 14604546 Human
carbonic anhydrase ix tumour Transmembrane carbonic anhydrase IX (CA IX) is frequently expressed in human tumours in response to hypoxia and may serve as a tumour marker and therapeutic target. 14604546 Human
ca9 adenomas In contrast, all benign lesions, including pyelonephritis, renal cysts, adenomas, oncocytomas, and normal kidney, did not express the MN/CA9 protein. 9230182 Human
ca9 oncocytoma Thus, we conclude that MN/CA9 protein expression could serve as a valuable adjunct to the cytological and histological diagnosis of benign renal cysts versus cystic RCC, adenoma versus RCC, and oncocytoma versus granular cell RCC. 9230182 Human
ca9 adenoma Thus, we conclude that MN/CA9 protein expression could serve as a valuable adjunct to the cytological and histological diagnosis of benign renal cysts versus cystic RCC, adenoma versus RCC, and oncocytoma versus granular cell RCC. 9230182 Human
ca9 clear-cell adenocarcinoma Absence of MN/CA9 expression in non-renal cell clear cell adenocarcinoma also indicates that MN/CA9 protein expression may be used as a differential diagnostic biomarker of metastatic clear cell RCC. 9230182 Human
the mn protein cervical carcinomas The MN protein is a newly described biomarker found to be overexpressed in most cervical carcinomas. 8946869 Human
carbonic anhydrase ix non-small-cell lung cancer Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. 12560438 Human
carbonic anhydrase ix tumor Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. 12560438 Human
carbonic anhydrase ix renal clear cell carcinoma Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. 12576453 Human
carbonic anhydrase ix tumor The G250 protein, also known as the carbonic anhydrase IX protein, is membranously expressed in all cases of clear cell RCC, and clinical studies have demonstrated exceptional tumor targeting with a G250 monoclonal antibody. 12946777 Human
ca9 liver metastases There was CA9 expression at the tumour-liver interface in only 16% of the BC liver metastases vs 54% of the CRC metastases (P=0.002). 15054467 Human
caix colon cancer We recently found that the proteasome inhibitor bortezomib decreases tumor carbonic anhydrase IX (CAIX) expression in colon cancer patients and herein report a companion laboratory study to test if this effect was the result of hypoxia-inducible factor (H 17308115 Human
caix diffuse astrocytomas We conclude that CAIX may be used as a prognostic indicator in diffuse astrocytomas to refine the information provided by grade. 17367605 Human
caix tumor Given the role of CAIX in the acidification of tumor environment and its up-regulation by hypoxia, it is thought that CAIX expression may be linked to resistance of tumor cells to radiotherapy by allowing them to acclimatize to a hypoxic and acidic microe 17367605 Human
carbonic anhydrase ix tumour Hypoxia-regulated carbonic anhydrase IX (CA IX) has been studied in various tumour sites and its expression has been correlated with the clinical outcome. 17213826 Human
carbonic anhydrase ix breast cancer The aim of our study was to evaluate the impact of HIF-1alpha and CA IX (carbonic anhydrase IX) (one of its target genes) expression on prognosis and treatment outcome of patients with breast cancer. 17245699 Human
carbonic anhydrase ix tumor PURPOSE: Published clinical studies provide conflicting data regarding the prognostic significance of carbonic anhydrase IX (CA IX) overexpression as an endogenous marker of tumor hypoxia and its comparability with other methods of hypoxia detection. 15752902 Human
carbonic anhydrase ix tumor In the first subgroup (n = 67), immunohistochemistry for carbonic anhydrase IX (CA IX) and glucose transporter-1 (GLUT-1) was performed on the pretreatment tumor biopsy. 15847702 Human
carbonic anhydrase ix tumor PURPOSE: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. 15897568 Human
carbonic anhydrase ix human tumours Transmembrane carbonic anhydrase IX (CA IX) is frequently expressed in human tumours in response to hypoxia and may serve as a tumour marker and therapeutic target. 14604546 Human
carbonic anhydrase ix monoclonal gammopathy of undetermined significance Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance. 15168117 Human
carbonic dehydratase lung cancer Alloalbumin venezia, selenium-binding protein 1, carbonic dehydratase, heat shock 20KD-like protein, and SM22 alpha protein were down-regulated in all 14 cases of lung cancer examined, whereas alpha enolase was consistently up-regulated. 15378762 Human
carbonic anhydrase ix breast tumors RESULTS: Regional loss of ER-alpha expression occurs in breast tumors and is consistently present in hypoxic regions defined by the proximity of necrosis and induction of hypoxia-induced genes carbonic anhydrase IX (CA-IX) and glucose transporter 1 (Glut- 15623657 Human
ca9 neoplasia Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. 10699902 Human
ca9 benign tumors METHODS: Reverse transcription polymerase chain reaction (RT-PCR) assays for MN/CA9 and PSMA were performed on RNAs extracted from 81 blood samples (59 patients with renal cancer, 7 with benign tumors, and 15 control volunteers). 10962301 Human
ca9 benign renal tumor No patient with a benign renal tumor exhibited MN/CA9 expression. 10430258 Human
ca9 tumors These results suggest that a novel replication-competent adenoviral vector mediated by MN/CA9 promoter, Ad-MN/CA9-E1a, can selectively replicate in MN/CA9-expressing tumors with cytotoxic effects and may be utilized for the treatment of uterine cervical c 15167900 Human
ca9 uterine cervical cancer These results suggest that a novel replication-competent adenoviral vector mediated by MN/CA9 promoter, Ad-MN/CA9-E1a, can selectively replicate in MN/CA9-expressing tumors with cytotoxic effects and may be utilized for the treatment of uterine cervical c 15167900 Human
ca9 metastasis A prognostic model based on a combination of clinical and molecular predictors included metastasis status, T stage, Eastern Cooperative Oncology Group PS, p53, CA9, and vimentin as predictors and had a C-index of 0.79, which was significantly higher (P < 15328185 Human
ca9 renal clear cell carcinoma CA9 expression as a prognostic factor in renal clear cell carcinoma. 15711113 Human
ca9 carcinoma Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. 15754010 Human
ca9 carcinoma Our results indicate that promoter methylation is not crucial for the control of CA9 gene expression in the non-RCC cell lines but could represent an accessory mechanism restricting its expression in highly dense carcinoma cell cultures. 15754010 Human
ca9 gastric cancer In vitro analysis revealed that loss of Ca9 expression in gastric cancer cell lines was restored after treatment with 5'-azadeoxycytidine and was associated with increased invasion (p<0.01). 15951534 Human
ca9 tumour While loss of Ca9 expression is regulated in part by methylation, re-expression of Ca9 is associated with increased invasion, supporting the hypothesis that increased Ca9 expression may contribute to invasion and thus advanced disease and tumour progressi 15951534 Human
ca9 gastric cancers While loss of Ca9 expression is regulated in part by methylation, re-expression of Ca9 is associated with increased invasion, supporting the hypothesis that increased Ca9 expression may contribute to invasion and thus advanced disease and tumour progressi 15951534 Human
ca9 primary carcinoma Firstly, primary carcinoma specimens were examined for CA9 expression by immunohistochemistry with M75 monoclonal antibody. 15856466 Human
ca9 vulvar cancer Our findings clearly indicate potential value of CA9 as a molecular marker for the assessment of regional lymph node status in vulvar cancer patients and support a possible utility of our RT-PCR assay in the detection of micrometastases. 15856466 Human
ca9 oligodendroglial neoplasms MATERIALS AND METHODS: 44 primary and 16 recurrent oligodendroglial neoplasms with 1p-aberrations were investigated immunohistochemically for the expression of DEC1, HIF-1alpha, and CA9. 16136500 Human
ca-9 tumor There was an inverse correlation with HER-2 gene amplification and expression of the tumor hypoxia marker CA-9 (chi(2) P = 0.02). 15217943 Human
ca9 primary cervical cancer CA9/CA12 expression was evaluated histochemically in primary cervical cancer tissues of 73 patients who underwent laparoscopic LN staging and two patients with clinical staging before definitive radiotherapy at the National Cancer Center, Korea. 17233814 Human
ca9 cancer CA9/CA12 expression was evaluated histochemically in primary cervical cancer tissues of 73 patients who underwent laparoscopic LN staging and two patients with clinical staging before definitive radiotherapy at the National Cancer Center, Korea. 17233814 Human
ca9 metastases These findings indicate that expression of CA9, but not CA12, in tumors is associated with the presence of LN metastases and poorer prognosis. 17233814 Human
ca9 tumors These findings indicate that expression of CA9, but not CA12, in tumors is associated with the presence of LN metastases and poorer prognosis. 17233814 Human
ca9 metastases Selective application of new treatment modalities based on CA9 expression to prevent LN metastases may improve overall treatment outcome in patients with uterine cervical cancer. 17233814 Human
ca9 uterine cervical cancer Selective application of new treatment modalities based on CA9 expression to prevent LN metastases may improve overall treatment outcome in patients with uterine cervical cancer. 17233814 Human
ca9 oncogene Renal tumour subtype/nephron segment-specific gene expression detected by RQ-PCR demonstrated that the tumour expressed relatively high amounts of alpha-methylacyl-CoA racemase (AMACR) and the KIT oncogene, but relatively low amounts of carbonic anhydrase 17323425 Human
carbonic anhydrase ix carcinoma Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. 15754010 Human
carbonic anhydrase ix cervical carcinomas Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. 14654550 Human
carbonic anhydrase ix chronic lymphocytic leukaemia (cll) The microvessel density (MVD), endothelial-cell proliferation (ECP) and carbonic anhydrase IX (CA IX) immunoreactivity were determined on 210 trephine biopsies from 57 patients with multiple myeloma (MM), 13 with acute myeloid leukaemia (AML), 48 with chr 15168117 Human
carbonic anhydrase ix haematological malignancies Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance. 15168117 Human
carbonic anhydrase ix necrosis The presence and extent of histologic necrosis of the primary tumors was recorded and correlated with clinicopathologic factors, carbonic anhydrase IX and Ki-67 expression, disease recurrence, and survival. 15880379 Human
carbonic anhydrase ix pancreatic cancer Immunohistochemistry confirmed that fibroblasts recruited into pancreatic cancer stroma strongly expressed carbonic anhydrase IX and keratin-8, whose transcripts were upregulated in KM104GFP-5G by oligonucleotide microarray analysis, whereas their express 15900602 Human
carbonic anhydrase ix primary tumors The presence and extent of histologic necrosis of the primary tumors was recorded and correlated with clinicopathologic factors, carbonic anhydrase IX and Ki-67 expression, disease recurrence, and survival. 15880379 Human
carbonic anhydrase ix renal cancer Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. 15897568 Human
carbonic anhydrase ix renal cancer PURPOSE: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. 15897568 Human
carbonic anhydrase ix tumors EXPERIMENTAL DESIGN: Tumors were harvested for histopathologic evaluation and immunohistochemistry (CD31, CD34; differentiation marker: involucrin; hypoxia markers: carbonic anhydrase IX, pimonidazole; vascular endothelial factor (VEGF) and Ki67) immediat 15585636 Human
carbonic anhydrase ix multiple myeloma (mm) The microvessel density (MVD), endothelial-cell proliferation (ECP) and carbonic anhydrase IX (CA IX) immunoreactivity were determined on 210 trephine biopsies from 57 patients with multiple myeloma (MM), 13 with acute myeloid leukaemia (AML), 48 with chr 15168117 Human
carbonic anhydrase ix transitional cell carcinoma of the bladder Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. 15069539 Human
ca9 clear cell adenocarcinoma Absence of MN/CA9 expression in non-renal cell clear cell adenocarcinoma also indicates that MN/CA9 protein expression may be used as a differential diagnostic biomarker of metastatic clear cell RCC. 9230182 Human
ca9 renal cell carcinoma MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. 10368188 Human
ca9 renal cell carcinoma (rcc) OBJECTIVE: To compare the levels of MN/CA9 expression with clinicopathological variables in renal cell carcinoma (RCC), and thus evaluate MN/CA9 expression as a possible biomarker for RCC. 10368188 Human
ca9 renal cell carcinoma These data suggest that hypomethylation in the 5' region may have a major role in expression of the MN/CA9 gene in renal cell carcinoma cells. 10708480 Human
ca9 head and neck cancers EXPERIMENTAL DESIGN: We assessed the expression of CA9 and the microvessel density (MVD; CD31-positive) in 75 locally advanced squamous cell head and neck cancers treated with concurrent chemoradiotherapy with carboplatin. 11705854 Human
ca9 renal tumor EXPERIMENTAL DESIGN: The expression of four genes in renal tumor was evaluated by quantitative reverse transcription-PCR: carbonic anhydrase IX (CA9), methylacyl-CoA racemase (AMACR), parvalbumin (PVALB), and chloride channel kb (CLCNKB). 16166433 Human
ca9 tumors The mRNA expression ratios among these genes (i.e., CA9/AMACR and AMACR/CLCNKB ratios) further accentuate the gene expression differences among these tumors, and a molecular diagnostic algorithm was established. 16166433 Human
ca9 tumor We also examined whether CA9 expression can be an indicator of reoxygenation of tumor by measuring its mRNA expression during fractionated radiotherapy. 16416108 Human
ca9 tumor Tumor CA9 expression was not altered following either 10 or 20 Gy of radiotherapy. 16416108 Human
ca9 metastasis Conclusion: The strong correlation between CA9 expression and metastasis suggests that CA9 expression might be an important indicator for identifying patients who require more aggressive systemic therapy. 16416108 Human
caix human tumours CAIX expression is linked to poor prognosis in a number of human tumours, and may be a marker of aggressive malignant phenotype and a mechanism of progression. 12838292 Human
caix bladder cancer This study directly compares CAIX and GLUT1 with pimonidazole binding in a prospective series of bladder cancer patients and also studies the prognostic significance of the markers, in combination with vascularity and proliferation, in a retrospective ser 14520462 Human
caix cancer RECENT FINDINGS: The detection of circulating cancer cells by reverse transcriptase/polymerase chain reaction techniques for the MN/CAIX gene, the identification of specific genetic alterations in circulating tumor DNA, as well as the demonstration of som 14560138 Human
caix tumor RECENT FINDINGS: The detection of circulating cancer cells by reverse transcriptase/polymerase chain reaction techniques for the MN/CAIX gene, the identification of specific genetic alterations in circulating tumor DNA, as well as the demonstration of som 14560138 Human
caix clear cell renal carcinoma MATERIALS AND METHODS: Immunohistochemical analysis using a CAIX and a Ki67 monoclonal antibody was performed on tissue microarrays constructed from paraffin embedded specimens from 224 patients treated with nephrectomy for clear cell renal carcinoma. 15126876 Human
caix metastasis CAIX is overexpressed in a variety of tumor types and associated with increased metastasis and poor prognosis. 15342400 Human
caix tumor CAIX is overexpressed in a variety of tumor types and associated with increased metastasis and poor prognosis. 15342400 Human
caix metastasis The relationship between smoking, preoperative Hgb, tumour CAIX expression, MVD, and Eppendorf pO2 measurements vs nodal metastasis and between these clinical and biological variables was assessed. 15754996 Human
caix tumour The relationship between smoking, preoperative Hgb, tumour CAIX expression, MVD, and Eppendorf pO2 measurements vs nodal metastasis and between these clinical and biological variables was assessed. 15754996 Human
caix renal cancer PURPOSE: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. 15897568 Human
caix tumor PURPOSE: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. 15897568 Human
caix renal cancer In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy. 15897568 Human
caix renal cancer EXPERIMENTAL DESIGN: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome. 15897568 Human
caix renal cell carcinoma CONCLUSIONS: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2-based therapy and may enhance prognostic information obtained from pathology specimens. 15897568 Human
caix breast cancer The purpose of this study is to investigate the role of carbonic anhydrase IX (CAIX) expression in predicting the response to epirubicin and disease-free survival (DFS) in breast cancer patients enrolled in a single institution trial of primary anthracycl 16954440 Human
caix breast cancer CAIX expression was assessed in 183 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin+tamoxifen as primary systemic treatment. 16954440 Human
caix breast cancer CAIX expression in breast cancer patients shows a negative predictive role of treatment efficacy in ER-positive patients on the adjuvant tamoxifen after primary chemo-endocrine therapy. 16954440 Human
carbonic anhydrase ix renal tumor EXPERIMENTAL DESIGN: The expression of four genes in renal tumor was evaluated by quantitative reverse transcription-PCR: carbonic anhydrase IX (CA9), methylacyl-CoA racemase (AMACR), parvalbumin (PVALB), and chloride channel kb (CLCNKB). 16166433 Human
carbonic anhydrase ix renal cell carcinoma High (>85%) expression of carbonic anhydrase IX in renal cell carcinoma tumors is a favorable prognostic marker and may predict response to interleukin-2 therapy. 16905977 Human
carbonic anhydrase ix tumors High (>85%) expression of carbonic anhydrase IX in renal cell carcinoma tumors is a favorable prognostic marker and may predict response to interleukin-2 therapy. 16905977 Human
carbonic anhydrase ix breast cancer Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. 16954440 Human
carbonic anhydrase ix breast cancer The purpose of this study is to investigate the role of carbonic anhydrase IX (CAIX) expression in predicting the response to epirubicin and disease-free survival (DFS) in breast cancer patients enrolled in a single institution trial of primary anthracycl 16954440 Human
carbonic anhydrase ix colon cancer We recently found that the proteasome inhibitor bortezomib decreases tumor carbonic anhydrase IX (CAIX) expression in colon cancer patients and herein report a companion laboratory study to test if this effect was the result of hypoxia-inducible factor (H 17308115 Human
carbonic anhydrase ix oncogene Renal tumour subtype/nephron segment-specific gene expression detected by RQ-PCR demonstrated that the tumour expressed relatively high amounts of alpha-methylacyl-CoA racemase (AMACR) and the KIT oncogene, but relatively low amounts of carbonic anhydrase 17323425 Human
carbonic anhydrase ix sarcomatoid renal cell carcinomas MATERIALS AND METHODS: Immunohistochemical staining for hypoxia inducible factor-1alpha, glucose transporter 1, carbonic anhydrase IX and vascular endothelial growth factor was performed in 22 clear cell and 12 nonclear cell sarcomatoid renal cell carcino 17382701 Human
carbonic anhydrase ix sarcomatoid renal cell carcinomas None of the nonclear cell sarcomatoid renal cell carcinomas showed 2+ or 3+ expression of hypoxia inducible factor-1alpha, carbonic anhydrase IX or glucose transporter 1, but 92% showed diffuse positivity for vascular endothelial growth factor. 17382701 Human
ca9 human renal cell carcinoma Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. 11506497 Human
caix metastatic nodal disease While neither current smoking status, tumour size, tumour oxygen measurements, MVD and CAIX expression correlated with metastatic nodal disease, a low preoperative Hgb correlated with pathological nodal status (p < 0.027). 15754996 Human
ca9 atypical hyperplasia The expression levels of DEC2, CA9, and SLC2A1 were significantly higher in the 4 atypical hyperplasia tissues and 82 endometrial carcinomas compared with those in the 21 normal endometria. 17342330 Human
ca9 gastric cancer Although a large study correlating HIF-1alpha expression with prognosis is lacking in gastric cancer, the immunohistochemical expression of HIF-1alpha target genes (Glut-1, VEGF, CA9, iNOS) is associated with a poor prognosis. 16290133 Human
ca9 metastatic renal cell carcinoma PURPOSE: A phase I peptide vaccination trial was done in patients with progressive cytokine-refractory metastatic renal cell carcinoma (RCC) to assess both the toxicity and capability to induce immune responses of three peptides (CA9p219-227, p288-296, an 16551861 Human
caix head and neck tumor The aim of this study was to compare tumor cell hypoxia assessed by the hypoxic cell marker pimonidazole (PIMO) with expression of the endogenous hypoxia-related marker carbonic anhydrase IX (CAIX) in three human head and neck tumor lines. 16024110 Human
caix phyllodes tumors METHODS: The expression of HIF-1alpha, CAIX, VEGF and p53 was investigated by immunohistochemistry in a group of 37 primary phyllodes tumors and 30 fibroadenomas with known clinical follow-up. 16168127 Human
carbonic anhydrase ix malignancy Understanding the genetic abnormalities related to the development of RCC (e.g., VHL gene abnormalities) and identifying molecular targets (e.g., epidermal growth factor, vascular endothelial growth factor and carbonic anhydrase IX) are playing a major ro 16262562 Human
carbonic anhydrase ix tumor Carbonic anhydrase IX and signaling via the epidermal growth factor receptor (EGFR) are involved in tumor cell proliferation and are also up regulated by mutation in the VHL gene. 16305462 Human
carbonic anhydrase ix astrocytic tumors Expression of Carbonic Anhydrase IX in Astrocytic Tumors Predicts Poor Prognosis. 16428489 Human
carbonic anhydrase ix gastric adenocarcinomas Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. 16495697 Human
ca9 lymph node metastasis Tissue sections of the primary tumour and a lymph node metastasis of 60 patients with breast cancer were immunohistochemically stained for the hypoxia-markers carbonic anhydrase 9 (CA9), hypoxia-inducible factor-1alpha (Hif-1alpha) and DEC-1 and for CD34/ 16251878 Human
ca9 lymph node metastases CA9 and Hif-1alpha expression were correlated (primary tumours P=0.005; lymph node metastases P<0.001). 16251878 Human
ca9 lymph node metastases Primary tumours and lymph node metastases with CA9 or Hif-1alpha expression had a higher ECP% and TCP% (P<0.003); in primary tumours, mixed/expansive growth pattern and fibrotic focus were characterised by higher ECP% (P=0.03). 16251878 Human
ca9 lymph node metastases Furthermore, between primary tumours and lymph node metastases a correlation was found for ECP%, TCP%, CA9 and Hif-1alpha expression (ECP% r=0.51, P<0.001; TCP r=0.77, P<0.001; CA9 and Hif-1alpha P<0.001). 16251878 Human
ca9 rcc Diffuse membraneous staining of all RCCs (with the exception of chromophobic cell RCC) suggests that MN/CA9 protein expression might have an important clinical utility in the early detection and treatment of RCC. 9230182 Human
ca9 rcc Absence of MN/CA9 expression in non-renal cell clear cell adenocarcinoma also indicates that MN/CA9 protein expression may be used as a differential diagnostic biomarker of metastatic clear cell RCC. 9230182 Human
ca9 rcc OBJECTIVE: To compare the levels of MN/CA9 expression with clinicopathological variables in renal cell carcinoma (RCC), and thus evaluate MN/CA9 expression as a possible biomarker for RCC. 10368188 Human
ca9 rcc CONCLUSION: These results suggest that MN/CA9 expression is a potential diagnostic biomarker of RCC, especially the clear-cell type, and can be targeted using molecular biological techniques. 10368188 Human
ca9 rcc These results suggest that hypomethylation in the 5' region may play an important role in the expression of MN/CA9 in RCC. 11215204 Human
ca9 rcc To reveal the activation mechanism, we investigated the relationship between methylation status of the MN/CA9 promoter region and gene expression using 13 human RCCs, and examined the effect of in vitro CpG methylation on the MN/CA9 promoter activity usin 11506497 Human
ca9 rcc To investigate the mechanism of MN/CA9 activation in RCC, we examined the methylation status of this gene in RCC cell lines and human tissue samples and found that hypomethylation in the promoter region may play an important role in the expression of MN/C 11771176 Human
ca9 neuroblastoma Herein, we investigated the HIF-1alpha-mediated gene expression of carbonic anhydrase 9 (CA9) in response to hypoxia and changes of intracellular calcium levels in the neuroblastoma cell line SH-SY5Y. 15322093 Human
ca9 rcc EXPERIMENTAL DESIGN: A custom tissue array was constructed using clear cell RCC from 318 patients, representing all stages of localized and metastatic RCC, and immunohistochemically stained for molecular markers Ki67, p53, gelsolin, CA9, CA12, PTEN, EpCAM 15328185 Human
ca9 rcc Our results indicate that promoter methylation is not crucial for the control of CA9 gene expression in the non-RCC cell lines but could represent an accessory mechanism restricting its expression in highly dense carcinoma cell cultures. 15754010 Human
ca9 malignant transformation BACKGROUND: Carbonic anhydrase IX (MN/Ca9) catalyses the reversible metabolism of carbon dioxide to carbonic acid and has also been linked to malignant transformation and hypoxia in various cancers. 15951534 Human
ca9 rcc Different kinds of biochemical and molecular markers such as ferritin, MN/CA9, apoptotic index, p53, IL-2, gamma-enolase, CD44, CD95, chromosome instability and loss of heterozygosity have been tested in RCC, but so far no marker fulfils one or the other 16191485 Human
ca9 fibrosarcoma Constitutively increased ERK activity in isogenic fibrosarcoma cell lines did not cause increased cell density-dependent CAIX expression/CA9 promoter activity. 16270297 Human
ca9 tumor-associated antigen PURPOSE: A phase I peptide vaccination trial was done in patients with progressive cytokine-refractory metastatic renal cell carcinoma (RCC) to assess both the toxicity and capability to induce immune responses of three peptides (CA9p219-227, p288-296, an 16551861 Human
ca9 rcc PURPOSE: A phase I peptide vaccination trial was done in patients with progressive cytokine-refractory metastatic renal cell carcinoma (RCC) to assess both the toxicity and capability to induce immune responses of three peptides (CA9p219-227, p288-296, an 16551861 Human
ca9 aml In a DNA microarray analysis of 116 AML samples, we found a significant correlation between high mRNA levels of G250/CA9 and longer overall survival (P = .022), a similar trend with high mRNA levels of PRAME (P = .103), and a hint for RHAMM/HMMR. 16931630 Human
ca9 mrd In conclusion, expression of the TAAs RHAMM/HMMR, PRAME, and G250/CA9 can induce strong antileukemic immune responses, possibly enabling MRD control. 16931630 Human
ca9 rcc A phase I clinical trial was performed with CA9-peptide-loaded dendritic cells (DCs) in patients with progressive, cytokine-refractory metastatic RCC to assess the safety, toxicity, and induction of CA9-specific immunity. 17198090 Human
ca9 meningiomas The purpose of this study was to evaluate the prevalence of hypoxia in meningiomas using the endogenous hypoxia marker carbonic anhydrase 9 (CA9) and to relate the expression of CA9 to tumor vascularity, histopathologic grade, and clinical variables, such 17200340 Human
ca9 tumor The purpose of this study was to evaluate the prevalence of hypoxia in meningiomas using the endogenous hypoxia marker carbonic anhydrase 9 (CA9) and to relate the expression of CA9 to tumor vascularity, histopathologic grade, and clinical variables, such 17200340 Human
ca9 recurrent tumor The purpose of this study was to evaluate the prevalence of hypoxia in meningiomas using the endogenous hypoxia marker carbonic anhydrase 9 (CA9) and to relate the expression of CA9 to tumor vascularity, histopathologic grade, and clinical variables, such 17200340 Human
ca9 grade 3 meningiomas EXPERIMENTAL DESIGN: Expression of CA9 and CD34, an endothelial cell marker, was examined in serial paraffin-embedded sections by immunohistochemistry in 25 grade 1, 17 grade 2, and 20 grade 3 meningiomas. 17200340 Human
caix tumor-associated antigen In view of the induction/up-regulation of G250 antigen in RCC, its restricted tissue expression and its possible role in therapy, we set out to molecularly define the G250 antigen, which we identified as a transmembrane protein identical to the tumor-asso 10709109 Human
caix rcc In view of the induction/up-regulation of G250 antigen in RCC, its restricted tissue expression and its possible role in therapy, we set out to molecularly define the G250 antigen, which we identified as a transmembrane protein identical to the tumor-asso 10709109 Human
caix rcc EXPERIMENTAL DESIGN: Immunohistochemical analysis using a CAIX monoclonal antibody was performed on tissue microarrays constructed from paraffin-embedded specimens from patients (N = 321) treated by nephrectomy for clear cell RCC. 12576453 Human
caix adenocarcinomas Both proteins showed highly significant elevations in CAIX-positive regions compared to CAIX-negative regions, and there was a nonsignificant trend for this effect to be greater in adenocarcinomas compared to squamous cell carcinomas. 14742261 Human
caix rcc DNase-I footprint and band-shift analysis demonstrated that Sp1 and HIF-1alpha proteins in nuclear extracts of RCC cells bind to the CAIX promoter and mutations in the most proximal Sp1 binding element or HIF binding element completely abolished CAIX prom 15184875 Human
caix breast tumors RESULTS: Regional loss of ER-alpha expression occurs in breast tumors and is consistently present in hypoxic regions defined by the proximity of necrosis and induction of hypoxia-induced genes carbonic anhydrase IX (CA-IX) and glucose transporter 1 (Glut- 15623657 Human
caix in-situ carcinomas Regional decrease of ER-alpha expression was consistently observed in peri-necrotic regions as compared to distant regions in both in-situ carcinomas (n=29, P <0.0001) and invasive carcinomas (n=20, P=0.0001), which was closely associated with the inducti 15777504 Human
caix invasive carcinomas Regional decrease of ER-alpha expression was consistently observed in peri-necrotic regions as compared to distant regions in both in-situ carcinomas (n=29, P <0.0001) and invasive carcinomas (n=20, P=0.0001), which was closely associated with the inducti 15777504 Human
caix fibrosarcoma Constitutively increased ERK activity in isogenic fibrosarcoma cell lines did not cause increased cell density-dependent CAIX expression/CA9 promoter activity. 16270297 Human
caix rcc Beside the previously identified genetic abnormalities (VHL, MET, EGFR), CAIX seems to be a novel molecular marker of RCC. 16554910 Human
caix tumor The aim of this investigation was to study associations between the putative endogenous hypoxia markers CA-IX, Glut-1 and Glut-3 and clinical tumor and patient characteristics and to evaluate the prognostic value of these markers. 16730088 Human
caix rcc The specificity and the prognostic value of CA-IX provide impetus to create a mouse model of CA-IX-expressing RCC for testing CA-IX-targeted therapies against RCC. 17095063 Mouse
carbonic anhydrase ix lymphoma Carbonic anhydrase IX (CA IX), a HIF-inducible membrane-bound enzyme, expression was not abundant with membranous staining being present in seven (8%) of the lymphoma cases and none of the reactive cases. 11895491 Human
carbonic anhydrase ix rcc The G250 protein, also known as the carbonic anhydrase IX protein, is membranously expressed in all cases of clear cell RCC, and clinical studies have demonstrated exceptional tumor targeting with a G250 monoclonal antibody. 12946777 Human
carbonic anhydrase ix malignant transformation BACKGROUND: Carbonic anhydrase IX (MN/Ca9) catalyses the reversible metabolism of carbon dioxide to carbonic acid and has also been linked to malignant transformation and hypoxia in various cancers. 15951534 Human
carbonic anhydrase ix rcc The use of carbonic anhydrase IX as a promising molecular marker in RCC is described by authors from Los Angeles, who discuss the promise that molecular markers hold to improve diagnosis, staging, treatment, surveillance and survival of patients with RCC. 16042714 Human
carbonic anhydrase ix rcc Understanding the genetic abnormalities related to the development of RCC (e.g., VHL gene abnormalities) and identifying molecular targets (e.g., epidermal growth factor, vascular endothelial growth factor and carbonic anhydrase IX) are playing a major ro 16262562 Human
carbonic anhydrase ix renal cancer In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer. 16361579 Human
carbonic anhydrase ix small cell lung cancer Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. 16513206 Human
carbonic anhydrase ix tumor The hypoxia-inducible enzyme carbonic anhydrase IX (CA IX) has recently been discussed as a surrogate marker of tumor hypoxia, an indicator of prognosis and a potential therapeutic target in malignant glioma. 16944313 Human
carbonic anhydrase ix malignant glioma The hypoxia-inducible enzyme carbonic anhydrase IX (CA IX) has recently been discussed as a surrogate marker of tumor hypoxia, an indicator of prognosis and a potential therapeutic target in malignant glioma. 16944313 Human
carbonic anhydrase ix tumor Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. 17030461 Human
carbonic anhydrase ix lung adenocarcinoma Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. 17030461 Human
carbonic anhydrase ix head and neck tumor The aim of this study was to compare tumor cell hypoxia assessed by the hypoxic cell marker pimonidazole (PIMO) with expression of the endogenous hypoxia-related marker carbonic anhydrase IX (CAIX) in three human head and neck tumor lines. 16024110 Human
ca9 lymph node metastasis CA9 expression was also associated with male sex, lymph node metastasis, and smoking history, but these correlations did not reach statistical significance. 18440050 Human
ca9 rcc These studies suggest that recombinant hsp110 complexed to CA9 should be evaluated for treatment of RCC. 17146628 Human
ca9 metastatic tumors At diagnosis, the average of CA9 gene expression was significantly lower (p = 0.004) in metastatic tumors (N+ or/and M+) than in non-metastatic tumors (N0M0). 17390110 Human
ca9 metastasis CA9 may be a potential marker for the prediction of early metastasis after nephrectomy and to guide post-operative follow-up and treatment. 17390110 Human
ca9 colorectal adenocarcinomas We studied the role of protein expression of hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, carbonic anhydrase 9 (CA9) and glucose transporter 1 (GLUT1) in patients with colorectal adenocarcinomas. 17452775 Human
ca9 colorectal adenocarcinomas METHODS: Expression of HIF-1alpha, HIF-2alpha, CA9 and GLUT1 was quantified by immunohistochemistry in 133 colorectal adenocarcinomas. 17452775 Human
ca9 cancer The present study was to evaluate MN/CA9 as a new molecular marker for the detection of cancer cells in pleural effusions. 17536770 Human
ca9 mesothelioma MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 1 17536770 Human
ca9 lung cancers MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 1 17536770 Human
caix recurrent endometrial carcinoma We conclude that MVD, CA-IX, and HIF-1alpha expression are not independent prognostic markers for recurrent endometrial carcinoma. 17359291 Human
caix endometrial carcinomas CONCLUSION: As p16 is consistently expressed in TM, less and only patchy expressed in the normal Fallopian tube, is paralleled by aberrant expression of cell cycle proteins, HIF-1alpha, CAIX and Glut-1 and resembles the pattern of p16 expression frequentl 17429140 Human
caix hyperplasia No membranous expression of Glut-1 and CAIX was noticed in inactive endometrium, in contrast with expression in hyperplasia (Glut-1 0%, CAIX 61%, only focal and diffuse) and carcinoma (Glut-1 94.6%, CAIX 92%, both mostly perinecrotically). 17452774 Human
caix metastatic renal cell cancer BACKGROUND: We have treated three patients with carboxy-anhydrase-IX (CAIX) positive metastatic renal cell cancer (RCC) by adoptive transfer of autologous T-cells that had been gene-transduced to express a single-chain antibody-G250 chimeric receptor [scF 17479266 Human
caix rcc BACKGROUND: We have treated three patients with carboxy-anhydrase-IX (CAIX) positive metastatic renal cell cancer (RCC) by adoptive transfer of autologous T-cells that had been gene-transduced to express a single-chain antibody-G250 chimeric receptor [scF 17479266 Human
caix gliomas Our findings of up-regulation of HIF-1alpha and its downstream targets VEGF, GLUT-1, and CAIX in higher-grade gliomas support this hypothesis. 17486380 Human
caix oncoproteins Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. 17489737 Human
caix cancer Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. 17489737 Human
caix oncoproteins Based on these targeted therapeutic approaches, this review describes clinical research studies performed with enzyme-linked immunosorbent assays specific for the circulating oncoproteins, HER2/neu, EGFR and CAIX. 17489737 Human
carbonic anhydrase ix tumor Previously, we showed that hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, carbonic anhydrase IX (CA IX), and vascular endothelial growth factor (VEGF) were frequently coexpressed in tumor biopsies from patients of nasopharyngeal carcinoma (NPC) and we 17320280 Human
carbonic anhydrase ix nasopharyngeal carcinoma (npc) Previously, we showed that hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, carbonic anhydrase IX (CA IX), and vascular endothelial growth factor (VEGF) were frequently coexpressed in tumor biopsies from patients of nasopharyngeal carcinoma (NPC) and we 17320280 Human
carbonic anhydrase ix breast cancer Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer. 17387339 Human
carbonic anhydrase ix human renal cell carcinoma Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. 17608827 Human
carbonic anhydrase ix tumor METHODS AND MATERIALS: We performed immunohistochemical staining of hypoxia-induced proteins (carbonic anhydrase IX [CA IX], BNIP3L, connective tissue growth factor, osteopontin, ephrin A1, hypoxia inducible gene-2, dihydrofolate reductase, galectin-1, Ik 17707270 Human
carbonic anhydrase ix hnscc METHODS AND MATERIALS: We performed immunohistochemical staining of hypoxia-induced proteins (carbonic anhydrase IX [CA IX], BNIP3L, connective tissue growth factor, osteopontin, ephrin A1, hypoxia inducible gene-2, dihydrofolate reductase, galectin-1, Ik 17707270 Human
carbonic anhydrase ix squamous cell carcinoma of the tongue Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. 18057013 Human
carbonic anhydrase ix squamous cell carcinoma of the tongue The purpose of this study is to determine the prognostic relevance of the expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein in surgically resected squamous cell carcinoma of the tongue. 18057013 Human
ca9 tumour PATIENTS AND METHODS: Sixty-seven patients with advanced head and neck carcinomas were studied for pre-treatment plasma osteopontin measured by ELISA, tumour oxygenation status using pO(2) needle electrodes and tumour osteopontin, hypoxia inducible factor 17499868 Human
ca9 head and neck carcinomas PATIENTS AND METHODS: Sixty-seven patients with advanced head and neck carcinomas were studied for pre-treatment plasma osteopontin measured by ELISA, tumour oxygenation status using pO(2) needle electrodes and tumour osteopontin, hypoxia inducible factor 17499868 Human
ca9 glioma Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. 17524506 Human
ca9 gbm BACKGROUND AND PURPOSE: To identify molecular markers of tumor hypoxia and potential therapeutic targets in glioblastoma (GBM), we investigated the hypoxia-related expression of osteopontin (OPN), carbonic anhydrase 9 (CA9), erythropoietin (EPO), vascular 17524506 Human
ca9 glioblastoma BACKGROUND AND PURPOSE: To identify molecular markers of tumor hypoxia and potential therapeutic targets in glioblastoma (GBM), we investigated the hypoxia-related expression of osteopontin (OPN), carbonic anhydrase 9 (CA9), erythropoietin (EPO), vascular 17524506 Human
ca9 human tumor BACKGROUND AND PURPOSE: To identify molecular markers of tumor hypoxia and potential therapeutic targets in glioblastoma (GBM), we investigated the hypoxia-related expression of osteopontin (OPN), carbonic anhydrase 9 (CA9), erythropoietin (EPO), vascular 17524506 Human
ca9 tumor BACKGROUND AND PURPOSE: To identify molecular markers of tumor hypoxia and potential therapeutic targets in glioblastoma (GBM), we investigated the hypoxia-related expression of osteopontin (OPN), carbonic anhydrase 9 (CA9), erythropoietin (EPO), vascular 17524506 Human
ca9 low-grade astrocytoma (lga) BACKGROUND AND PURPOSE: To identify molecular markers of tumor hypoxia and potential therapeutic targets in glioblastoma (GBM), we investigated the hypoxia-related expression of osteopontin (OPN), carbonic anhydrase 9 (CA9), erythropoietin (EPO), vascular 17524506 Human
ca9 gbm CONCLUSIONS: Among a panel of known hypoxia-inducible genes, OPN and CA9 emerge as most consistently induced by in vitro hypoxia in human GBM cell lines and most specifically expressed in patient GBM tumor tissue, rendering these two genes attractive targ 17524506 Human
ca9 tumor CONCLUSIONS: Among a panel of known hypoxia-inducible genes, OPN and CA9 emerge as most consistently induced by in vitro hypoxia in human GBM cell lines and most specifically expressed in patient GBM tumor tissue, rendering these two genes attractive targ 17524506 Human
ca9 solid tumors PURPOSE: Carbonic anhydrase 9 (CA9) is over-expressed in many human solid tumors under conditions of low oxygen concentration and can be associated with a low probability of survival. 17724612 Human
ca9 tumors CONCLUSION: Our results suggest the possibility that CA9 over-expression in tumors might be exploited to increase the treatment effects of TPZ. 17724612 Human
ca9 head cancer Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. 17852557 Human
ca9 cancer RESULTS: HIF1alpha and HIF2alpha were expressed in the nuclei and cytoplasm of cancer cells, while CA9 had a membrane reactivity. 17852557 Human
ca9 tumour Here we describe an alternative splicing variant of the CA9 mRNA, which does not contain exons 8-9 and is expressed in tumour cells independently of hypoxia. 18026188 Human
ca9 metastasis In the first data set, individual comparison with clinical data combined with adjustment for multiple testing and multivariate analysis revealed potentially relevant alteration of CA9, DKK1, EGR1, HEY2, MYC, MYCN, TERT, TOP2A, TRIM22, and VEGF expression 18260125 Human
ca9 carcinomas Carbonic anhydrase IX (CA9) is reportedly overexpressed in several types of carcinomas, but little is known about the expression pattern of CA9 in oral cavity cancer and the corresponding normal tissues. 18440050 Human
ca9 oral cavity cancer Carbonic anhydrase IX (CA9) is reportedly overexpressed in several types of carcinomas, but little is known about the expression pattern of CA9 in oral cavity cancer and the corresponding normal tissues. 18440050 Human
ca9 oral cavity squamous cell carcinoma We aimed to assess the prevalence of CA9 expression and its prognostic implications in patients with oral cavity squamous cell carcinoma (SCC). 18440050 Human
ca9 tumors Among 117 samples, 68 (58.1%) tumors displayed CA9 overexpression. 18440050 Human
ca9 bladder carcinoma Here we show that CA9, when expressed heterologously in cultured spheroids (0.5-mm diameter, ~25,000 cells) of RT112 cells (derived from bladder carcinoma), induces a near-uniform intracellular pH (pH(i)) throughout the structure. 18482982 Human
ca9 tumors By disrupting spatial pH(i) control, inhibition of CA9 activity may offer a novel strategy for the clinical treatment of CA9-associated tumors. 18482982 Human
ca9 colorectal adenocarcinomas Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis. 18728663 Human
ca9 colorectal cancer (crc) Stromal expression of hypoxia inducible factor 2 alpha (HIF-2 alpha) and carbonic anhydrase 9 (CA9) are associated with a poorer prognosis in colorectal cancer (CRC). 18728663 Human
ca 9 uterine cervical cancer Elevation of uterine cervical cancer hypoxia markers such as HIF 1a, CA 9, GLUT-1 is combined with poorer clinical outcome prognosis. 18159826 Human
caix tumor Several molecules including growth factors (e.g., VEGF, CTGF), growth factor receptors (CD105, VEGFRs), adhesion molecules (alphavbeta3 integrin), and enzymes (CAIX, FAPalpha, MMPs, PSMA, uPA) are induced or upregulated in the tumor microenvironment which 17661033 Human
caix clear cell renal cell carcinoma (ccrcc) PURPOSE: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). 17947723 Human
caix ccrcc We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up. 17947723 Human
caix ccrcc Although CAIX is associated with outcome in patients with ccRCC, it is not an independent prognostic marker. 17947723 Human
caix prostate tumors CONCLUSIONS: These findings have demonstrated an intimate relationship among CAIX, VEGF, pAkt, and Bcl-2 in prostate tumors. 17991582 Mouse
caix tumor Thus, CAIX might prove effective as a potential marker of tumor radiation resistance. 17991582 Mouse
caix invasive squamous cell carcinoma (iscc) METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human
caix cervical intraepithelial neoplasia METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human
caix cin METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human
caix cervical carcinoma RESULTS: CAIX and MET were expressed in cervical carcinoma cell lines, but not in normal or human papillomavirus-immortalized cervical cells. 18055005 Human
caix cin GLUT1 was expressed in nearly all cases of CIN and ISCC, however, CAIX was expressed only in CIN III and ISCC. 18055005 Human
caix carcinogenesis CAIX expression, an acid-resistant phenotype, may be a powerful adaptive advantage during carcinogenesis. 18055005 Human
caix rcc Multivariate analysis retained HIF-1 alpha and CAIX expression as the strongest independent prognostic factors for patients with metastatic clear cell RCC. 18094421 Human
caix tumor Because HIF-1 alpha and CAIX are independently and differentially regulated in metastatic clear cell RCC, both tumor markers can be complementary in predicting prognosis. 18094421 Human
caix rcc Because HIF-1 alpha and CAIX are independently and differentially regulated in metastatic clear cell RCC, both tumor markers can be complementary in predicting prognosis. 18094421 Human
caix clear cell renal cell carcinoma Immunohistochemical (IHC) studies show that CAIX is diffusely overexpressed in clear cell renal cell carcinoma (CRCC), making it a potentially important differential diagnostic marker. 18300814 Human
caix tumor Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. 18464292 Human
caix clear cell renal cell carcinoma Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. 18464292 Human
caix tumor We attempted to describe, in a series of clear cell renal cell carcinoma (RCC), the relationship between CAIX expression, VHL gene mutations, tumor characteristics and outcome. 18464292 Human
caix clear cell renal cell carcinoma We attempted to describe, in a series of clear cell renal cell carcinoma (RCC), the relationship between CAIX expression, VHL gene mutations, tumor characteristics and outcome. 18464292 Human
caix rcc We attempted to describe, in a series of clear cell renal cell carcinoma (RCC), the relationship between CAIX expression, VHL gene mutations, tumor characteristics and outcome. 18464292 Human
caix tumors Tumors with VHL mutation showed higher CAIX expression than those without (p = 0.02). 18464292 Human
caix metastases Low CAIX expression and absence of VHL mutation were associated with a more advanced tumors e.g., higher T stages and presence of metastases. 18464292 Human
caix tumors Low CAIX expression and absence of VHL mutation were associated with a more advanced tumors e.g., higher T stages and presence of metastases. 18464292 Human
caix rcc Taken together, CAIX expression and VHL mutational status are able to stratify patients with clear cell RCC into distinct groups with regards to clinicopathological variables and prognosis, with low CAIX expression and absence of VHL mutation being associ 18464292 Human
caix colorectal carcinomas The expression of hypoxia-inducible factor-1alpha and 13 hypoxia-inducible factor-1 target genes (AMF, CAIX, VEGF, VEGFR1, VEGFR2, HGF, MET, TGFalpha, EGFR, IGF2, MMP2, PLAUR, NIX) was quantified by real-time polymerase chain reaction in 18 colorectal, po 18619649 Human
caix poorly differentiated neuroendocrine carcinomas The expression of hypoxia-inducible factor-1alpha and 13 hypoxia-inducible factor-1 target genes (AMF, CAIX, VEGF, VEGFR1, VEGFR2, HGF, MET, TGFalpha, EGFR, IGF2, MMP2, PLAUR, NIX) was quantified by real-time polymerase chain reaction in 18 colorectal, po 18619649 Human
caix glioblastoma Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. 18636206 Human
caix carcinogenesis In early esophageal carcinogenesis, LC3 expression correlated with Ki-67 labeling index (p=0.0001), but showed no significant association with CAIX expression. 18695874 Human
caix clear cell renal cell carcinoma (ccrcc) This study aimed to investigate whether the expression of carbonic anhydrase IX (CAIX) is associated with the expression of vascular endothelial growth factor (VEGF) and whether the co-expression of the two correlates with survival outcome in clear cell r 18695901 Human
caix ccrcc The expression of CAIX and VEGF was evaluated immunohistochemically in 122 paraffin-embedded ccRCC specimens. 18695901 Human
caix metastasis Furthermore, CAIX expression significantly stratified the DSS of patients with high-stage (p=0.0001), high-grade (p=0.0392), low-grade (p=0.0273), metastasis (p=0.0034), no metastasis (p=0.0303) and ECOG-PS=0 (p=0.0003). 18695901 Human
caix metastasis A multivariate Cox regression analysis showed that tumor stage (p=0.0054), metastasis (p=0.0193), ECOG-PS (p=0.0065) and CAIX expression (p=0.0001) were independent prognostic factors of DSS. 18695901 Human
caix tumor A multivariate Cox regression analysis showed that tumor stage (p=0.0054), metastasis (p=0.0193), ECOG-PS (p=0.0065) and CAIX expression (p=0.0001) were independent prognostic factors of DSS. 18695901 Human
caix ccrcc In patients with ccRCC, CAIX and VEGF expression correlated inversely. 18695901 Human
caix laryngeal carcinoma Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. 18722267 Human
caix laryngeal carcinoma PURPOSE: To examine the prognostic value of three endogenous hypoxia markers (hypoxia inducible factor 1 alpha subunit [HIF1 alpha], carbonic anhydrase IX [CA-IX], and glucose transporter type 1 [GLUT-1]) on the clinical outcome in patients with early-sta 18722267 Human
caix glottic carcinoma PURPOSE: To examine the prognostic value of three endogenous hypoxia markers (hypoxia inducible factor 1 alpha subunit [HIF1 alpha], carbonic anhydrase IX [CA-IX], and glucose transporter type 1 [GLUT-1]) on the clinical outcome in patients with early-sta 18722267 Human
caix glottic squamous cell carcinoma METHODS AND MATERIALS: Immunohistochemistry for HIF1 alpha, CA-IX, and GLUT-1 was performed on formalin-fixed, paraffin-embedded, pretreatment tissue samples of 91 glottic squamous cell carcinoma specimens. 18722267 Human
caix tumors Tumors with a nonhypoxic profile (defined as low HIF1 alpha and low CA-IX expression) had significantly better local control (HR, 6.32; p = 0.013). 18722267 Human
caix laryngeal carcinomas CONCLUSION: The results of our study have shown that early-stage glottic laryngeal carcinomas with low HIF1 alpha and CA-IX expression are highly curable with RT. 18722267 Human
caix tumors For tumors with HIF1 alpha or CA-IX overexpression, hypoxic modification before RT or primary surgical treatment should be considered. 18722267 Human
carbonic anhydrase ix basal cell carcinomas Expression of some proteins recently reported to be characteristic of basal cell carcinomas was also assessed, namely, CK5-6, caveolin-1, carbonic anhydrase IX, p63, and CD117; these also constitute potential targets for therapies for aggressive tumors. 17316758 Human
carbonic anhydrase ix tumors Expression of some proteins recently reported to be characteristic of basal cell carcinomas was also assessed, namely, CK5-6, caveolin-1, carbonic anhydrase IX, p63, and CD117; these also constitute potential targets for therapies for aggressive tumors. 17316758 Human
carbonic anhydrase ix muscle-invasive bladder cancer Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer. 17706406 Human
carbonic anhydrase ix clear cell renal cell carcinoma (ccrcc) PURPOSE: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). 17947723 Human
carbonic anhydrase ix ovarian carcinoma Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. 17949239 Human
carbonic anhydrase ix tumour We also report that SLUG expression in tumour tissues correlates with that of the hypoxia survival gene carbonic anhydrase IX. 17973239 Human
carbonic anhydrase ix breast carcinoma In this regard, we report that the exposure of SLUG-negative/luminal-like MCF-7 cells to a hypoxic environment promotes the onset of the basal-like breast carcinoma phenotype, together with up-regulation of the SLUG gene, which in turn blunts oestrogen re 17973239 Human
carbonic anhydrase ix tumour Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. 18026188 Human
carbonic anhydrase ix human tumor Specific antibodies interfere with the function of human tumor-associated carbonic anhydrase IX (CA IX), and show potential as tools for anticancer interventions. 18041760 Human
carbonic anhydrase ix invasive squamous cell carcinoma (iscc) METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human
carbonic anhydrase ix cervical intraepithelial neoplasia METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human
carbonic anhydrase ix cin METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human
carbonic anhydrase ix tumor Examples include plasma VEGF levels, VHL gene mutation status and carbonic anhydrase IX levels in tumor tissue, among others. 18062748 Human
carbonic anhydrase ix clear cell renal carcinoma Radioisotope labeled chimeric G250, a monoclonal antibody to carbonic anhydrase IX antigen, has shown the potential to target clear cell renal carcinoma with high sensitivity and specificity. 18090499 Human
carbonic anhydrase ix brain tumors Carbonic anhydrase IX in oligodendroglial brain tumors. 18173856 Human
carbonic anhydrase ix soft tissue sarcomas We investigated the number of core biopsies required to accurately classify soft tissue sarcomas with respect to their expression of carbonic anhydrase IX (CA IX), a potential prognostic marker with a sparse and heterogeneous expression pattern. 18180112 Human
carbonic anhydrase ix tumor Tumor size, percentage of positive axillary nodes and expression status for the progesterone receptor, Ki-67 and carbonic anhydrase IX demonstrated independent prognostic significance with respect to relapse-free survival. 18194560 Human
carbonic anhydrase ix clear cell renal cell carcinoma Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. 18300814 Human
carbonic anhydrase ix tumor Carbonic anhydrase IX (hCA IX) is a membrane-associated glycoprotein that is observed in many tumor tissues and is strongly overexpressed by hypoxia conditions. 18336316 Human
carbonic anhydrase ix high-risk breast cancer Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials. 18355402 Human
carbonic anhydrase ix renal cell carcinoma Carbonic anhydrase IX is a von Hippel-Lindau mediated enzyme that is expressed in most renal cell carcinoma cases. 18423738 Human
carbonic anhydrase ix cancer Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. 18430114 Human
carbonic anhydrase ix renal cell carcinoma Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. 18430119 Human
carbonic anhydrase ix kidney cancer Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. 18430120 Human
carbonic anhydrase ix renal cell carcinoma Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. 18430123 Human
carbonic anhydrase ix transitional cell carcinoma of the bladder The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. 18430124 Human
carbonic anhydrase ix oral squamous cell carcinoma Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. 18440050 Human
carbonic anhydrase ix carcinomas Carbonic anhydrase IX (CA9) is reportedly overexpressed in several types of carcinomas, but little is known about the expression pattern of CA9 in oral cavity cancer and the corresponding normal tissues. 18440050 Human
carbonic anhydrase ix oral cavity cancer Carbonic anhydrase IX (CA9) is reportedly overexpressed in several types of carcinomas, but little is known about the expression pattern of CA9 in oral cavity cancer and the corresponding normal tissues. 18440050 Human
carbonic anhydrase ix leiomyoma In contrast, none of the hypoxia-related markers hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, glucose transporter-1, or carbonic anhydrase IX were expressed in any leiomyoma. 18559518 Human
carbonic anhydrase ix clear cell renal cell carcinoma Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. 18565906 Human
carbonic anhydrase ix tumors All tumors showed strongly positive immunohistochemical staining for cytokeratin 7 and carbonic anhydrase IX and negative immunostaining with antibodies against alpha-methylacyl-CoA racemase, CD10, and transcription factor E3. 18594469 Human
carbonic anhydrase ix clear cell renal cell carcinoma Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. 18669472 Human
carbonic anhydrase ix clear cell renal cell carcinomas Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component. 18669473 Human
carbonic anhydrase ix clear cell renal cell carcinoma Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. 18695901 Human
carbonic anhydrase ix clear cell renal cell carcinoma (ccrcc) This study aimed to investigate whether the expression of carbonic anhydrase IX (CAIX) is associated with the expression of vascular endothelial growth factor (VEGF) and whether the co-expression of the two correlates with survival outcome in clear cell r 18695901 Human
carbonic anhydrase ix laryngeal carcinoma PURPOSE: To examine the prognostic value of three endogenous hypoxia markers (hypoxia inducible factor 1 alpha subunit [HIF1 alpha], carbonic anhydrase IX [CA-IX], and glucose transporter type 1 [GLUT-1]) on the clinical outcome in patients with early-sta 18722267 Human
carbonic anhydrase ix glottic carcinoma PURPOSE: To examine the prognostic value of three endogenous hypoxia markers (hypoxia inducible factor 1 alpha subunit [HIF1 alpha], carbonic anhydrase IX [CA-IX], and glucose transporter type 1 [GLUT-1]) on the clinical outcome in patients with early-sta 18722267 Human
carbonic anhydrase ix tumors Carbonic anhydrase IX (CA IX) and, to a lesser extent, carbonic anhydrase XII (CA XII) are highly overexpressed in hypoxic tumors. 18806891 Human
ca9 renal cell carcinoma OBJECTIVE: To compare the levels of MN/CA9 expression with clinicopathological variables in renal cell carcinoma (RCC), and thus evaluate MN/CA9 expression as a possible biomarker for RCC. 10368188 Human
ca9 low-grade astrocytoma BACKGROUND AND PURPOSE: To identify molecular markers of tumor hypoxia and potential therapeutic targets in glioblastoma (GBM), we investigated the hypoxia-related expression of osteopontin (OPN), carbonic anhydrase 9 (CA9), erythropoietin (EPO), vascular 17524506 Human
ca9 colorectal cancer Stromal expression of hypoxia inducible factor 2 alpha (HIF-2 alpha) and carbonic anhydrase 9 (CA9) are associated with a poorer prognosis in colorectal cancer (CRC). 18728663 Human
caix clear cell renal cell carcinoma PURPOSE: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). 17947723 Human
caix invasive squamous cell carcinoma METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human
caix clear cell renal cell carcinoma This study aimed to investigate whether the expression of carbonic anhydrase IX (CAIX) is associated with the expression of vascular endothelial growth factor (VEGF) and whether the co-expression of the two correlates with survival outcome in clear cell r 18695901 Human
carbonic anhydrase ix chronic lymphocytic leukaemia The microvessel density (MVD), endothelial-cell proliferation (ECP) and carbonic anhydrase IX (CA IX) immunoreactivity were determined on 210 trephine biopsies from 57 patients with multiple myeloma (MM), 13 with acute myeloid leukaemia (AML), 48 with chr 15168117 Human
carbonic anhydrase ix multiple myeloma The microvessel density (MVD), endothelial-cell proliferation (ECP) and carbonic anhydrase IX (CA IX) immunoreactivity were determined on 210 trephine biopsies from 57 patients with multiple myeloma (MM), 13 with acute myeloid leukaemia (AML), 48 with chr 15168117 Human
carbonic anhydrase ix invasive squamous cell carcinoma METHODS: We analyzed the expression of the hypoxia-regulated genes, including hypoxia-inducible factor-1alpha (HIF-1alpha), erythropoietin (Epo), vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX), and M 18055005 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.